Lorazepam
Lorazepam (Ativan) is a benzodiazepine for anxiety and seizures; it causes dependence, is dangerous with opioids or alcohol, and withdrawal can be dangerous.
Overview
Lorazepam, sold under the brand name Ativan, is a benzodiazepine used for anxiety, for certain seizure emergencies, and as a sedative before medical procedures. It is intermediate-acting and, like all benzodiazepines, effective but carrying a real risk of tolerance and dependence with regular use. The standard benzodiazepine cautions apply: it is dangerous combined with opioids, alcohol, or other depressants, and stopping abruptly after regular use can be medically dangerous. It is widely prescribed and also misused, and counterfeit benzodiazepine pills are an increasing illicit-market hazard.
Source: MedlinePlus; DEA; PubChem CID 3958
Chemistry & mechanism of action
Lorazepam enhances the calming effect of GABA, the brain's main inhibitory neurotransmitter, slowing central nervous system activity to reduce anxiety, suppress certain seizures, and produce sedation. As with the whole class, this CNS suppression is why benzodiazepines are dangerous in overdose and especially in combination with other depressants, where breathing can slow too far. Repeated use leads the brain to adapt, producing tolerance and physical dependence; abrupt removal then leaves the nervous system over-excited, the basis of a potentially dangerous withdrawal syndrome. Lorazepam's intermediate duration shapes how quickly its effects and withdrawal appear.
Source: MedlinePlus; PubChem CID 3958
Effects
Lorazepam reduces anxiety and produces sedation, drowsiness, and muscle relaxation. Common effects include fatigue, dizziness, poor coordination, slurred speech, and impaired memory and concentration; some people experience paradoxical agitation. It impairs driving and tasks requiring alertness. With repeated use, tolerance develops and dependence can form; stopping abruptly after regular use can cause rebound anxiety and insomnia and, in more serious cases, a dangerous withdrawal that includes seizures. Its intermediate half-life means withdrawal can begin relatively soon after the last dose compared with longer-acting benzodiazepines.
Source: MedlinePlus
Risks & harms
Lorazepam carries the two central benzodiazepine dangers. First, combination with other depressants: taken with opioids, alcohol, or other sedatives, it compounds the suppression of breathing and is a frequent factor in fatal overdoses, with explicit regulatory warnings about benzodiazepine-and-opioid combinations. Second, withdrawal: after regular use, stopping suddenly can trigger seizures and other dangerous symptoms, so it must be tapered gradually under medical supervision rather than stopped abruptly and alone. The counterfeit market adds a third danger — pills sold illicitly as Ativan may contain other benzodiazepines, unrelated drugs, or fentanyl in unpredictable amounts, so naloxone (over the counter in the U.S. since 2023) is worth having because these pills can cause an opioid overdose. If you suspect an opioid overdose from a counterfeit pill, give naloxone and call 911. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; DEA; FDA; SAMHSA
Legal status (US)
In the United States, lorazepam is a Schedule IV controlled substance under the Controlled Substances Act: it has an accepted medical use and a lower abuse potential than Schedule II or III drugs, but it still carries a recognized risk of abuse and dependence and is available only by prescription, with limits on refills. Possessing or selling it without a valid prescription is illegal, and counterfeit versions are illicit drugs regardless of labeling. Internationally, lorazepam is controlled under the United Nations Convention on Psychotropic Substances and is recognized by the World Health Organization as an essential medicine, so most countries permit its medical use while controlling it. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971); WHO
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 3958PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C15H10Cl2N2O2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)ClPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- DIWRORZWFLOCLC-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- ativan, Ativan, Temesta, Loraz, Wypax, Almazine, Anxiedin, Lorabenz, Orfidal, Lorazepam Intensol, LorazepamumPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Lorazepam is an intermediate-acting benzodiazepine used for anxiety, for sedation before procedures, and to stop prolonged seizures (status epilepticus). It enhances GABA to reduce anxiety and produce sedation and muscle relaxation. Pharmacologically it stands apart within the class: it has no active metabolites and is cleared by a liver pathway (glucuronidation) that is comparatively preserved when liver function is reduced, which is why it is often chosen for people with impaired livers or the critically ill.PubChem CID 3958 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Lorazepam carries the benzodiazepine dangers — sedation, drowsiness, impaired coordination, tolerance and dependence — and, as with the class, its lethal risk lies in combination: mixed with opioids or alcohol it can suppress breathing fatally. Its lack of long-lasting active metabolites makes its effects comparatively predictable, but dependence still develops, and abrupt withdrawal after regular use can cause seizures and be life-threatening, so it too requires a supervised taper. Its injectable use in hospital adds the risk of over-sedation when given for agitation or seizures.PubChem CID 3958 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Lorazepam's labelling carries the benzodiazepine–opioid boxed warning: the combination can prove fatal through profound sedation and suppressed breathing, and is to be avoided unless there is no alternative. Alcohol and other CNS depressants heighten the sedation. Notably, because lorazepam is cleared by glucuronidation rather than the CYP enzyme system, it has fewer of the metabolic drug interactions seen with some other benzodiazepines — a distinction its labelling reflects.DailyMed §7 / boxed warning ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 118different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 118 variants
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- RX 773
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUN PHARMACEUTICAL INDUSTRIES INC
- Schedule
- CIV
- NDC
- 63304-773 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- E 2
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 62559-196 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- E 3
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 62559-197 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- RX7
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUN PHARMACEUTICAL INDUSTRIES INC
- Schedule
- CIV
- NDC
- 63304-772 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-008 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 71335-1694 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 72789-376 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- A BPI 63
- Color
- white
- Shape
- PENTAGON (5 sided)
- Form
- TABLET
- Labeler
- Bausch Health US LLC
- Schedule
- CIV
- NDC
- 0187-0063 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- A BPI 64
- Color
- white
- Shape
- PENTAGON (5 sided)
- Form
- TABLET
- Labeler
- Bausch Health US LLC
- Schedule
- CIV
- NDC
- 0187-0064 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-764 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- A 2 BPI 65
- Color
- white
- Shape
- PENTAGON (5 sided)
- Form
- TABLET
- Labeler
- Bausch Health US LLC
- Schedule
- CIV
- NDC
- 0187-0065 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Redpharm Drug
- Schedule
- CIV
- NDC
- 67296-2238 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-768 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- DirectRx
- Schedule
- CIV
- NDC
- 72189-351 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- E 1
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 62559-195 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-3423 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Clinical Solutions Wholesale, LLC
- Schedule
- CIV
- NDC
- 58118-1095 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Clinical Solutions Wholesale, LLC
- Schedule
- CIV
- NDC
- 58118-1096 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-2442 ↗ · 2026-06-18
- Strength
- LORAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-998 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-996 ↗ · 2026-06-18
- Strength
- LORAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-997 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIV
- NDC
- 68071-5068 ↗ · 2026-06-18
- Strength
- LORAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Preferred Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 68788-7355 ↗ · 2026-06-18
Dosage
Pending medical reviewer
